ALKERMES, INC.
WALTHAM, MA

Alkermes, Inc., headquartered in Waltham, Massachusetts, is a globally recognized biopharmaceutical company dedicated to developing innovative medicines for central nervous system (CNS) disorders. Founded as a venture to address unmet medical needs and challenges associated with debilitating diseases such as schizophrenia, depression, addiction, and multiple sclerosis, Alkermes leverages its scientific expertise and proprietary technologies across all aspects of drug development. Under the leadership of CEO Richard Pops since 1991, Alkermes has evolved from a modest startup to an impactful international company employing over 2,000 individuals. With a diversified commercial product portfolio and substantial clinical pipeline focused on CNS diseases, the company's growth trajectory is promising. Its commitment to addressing real-world challenges faced by patients and healthcare providers underpins its development strategies. James Robinson serves as President and COO, drawing on his extensive background in sales, marketing, regulatory affairs, and human resources, while Kathy Biberstein oversees key legal and operational functions. Complementing the executive team, Iain Brown manages financial operations with a seasoned perspective garnered from over 20 years in biopharmaceuticals. Alkermes maintains robust research initiatives targeting CNS disease treatment areas and has demonstrated a commitment to innovation through its pipeline of novel product candidates. The company's financial foundation is fortified by both its successful commercial operations and strategic pipeline advancements, ensuring sustained growth and contribution to the health sector. With an eye towards the future, Alkermes remains enthusiastic about expanding its impact on patient care and scientific advancement. For further information, please visit Alkermes' website at alkermes.com.